
Amniotics Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Amniotics
Access all reports
Amniotics AB is a Swedish biotechnology company focused on developing stem cell-based therapeutics for severe, life-threatening diseases. The company specializes in mesenchymal stem cells (MSCs) derived from amniotic fluid, which are used to create targeted treatments for various conditions. Amniotics has developed several product candidates, including PulmoStem, aimed at treating lung diseases, CogniStem for central nervous system disorders, NephroStem for kidney conditions, and CutiStem for skin therapies. The company is headquartered in Lund, Sweden, and its shares are listed on the Stockholm Stock Exchange.
Latest articles
)
Robert G. Hagstrom: Darwinian Investing and Multidisciplinary Wisdom
Robert G. Hagstrom, author of The Warren Buffett Way, explores how interdisciplinary thinking shapes his investing, from Adler's reading to Darwinian markets.
7 Feb 2025
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
Ticker symbol
AMNI
Country
🇸🇪 Sweden